Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PGN EDO51

Next Previous
Drug Profile

PGN EDO51

Alternative Names: EDO-51; PGN-EDO23; PGN-EDO51

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pepgen Corporation
  • Class Antisense oligonucleotides; Drug conjugates; Morpholines; Peptide drug conjugates; Protein-drug conjugates
  • Mechanism of Action Dystrophin expression stimulants; RNA splicing modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 28 May 2025 Discontinued - Phase-I for Duchenne muscular dystrophy (In adults) in United Kingdom, Canada, USA (IV)
  • 28 May 2025 Discontinued - Phase-II for Duchenne muscular dystrophy (In adolescents, In children) in United Kingdom (IV)
  • 28 May 2025 Discontinued - Phase-II for Duchenne muscular dystrophy (In adolescents, In children, In adults) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top